Suzetrigine and the Future of Non-Addictive Pain Management in the Midst of the U.S. Opioid Epidemic
Abstract
Chronic pain is a widespread and costly health crisis affecting people globally. It is a leading cause of disability, mental health disorders, and opioid dependence, with an annual economic impact of approximately $560 billion in the U.S. Despite its prevalence, effective non-opioid pain management options remain scarce, and the overuse of opioids has contributed to addiction and overdose deaths. This underscores the urgent need for safer, non-addictive treatments. Acute pain, if not properly managed, can transition into chronic pain, increasing the likelihood of long-term use of opioid. Studies show that up to 20% of patients with severe acute pain develop chronic pain, while opioid use after surgery can lead to dependence. Suzetrigine (VX-548), a novel NaV1.8 inhibitor, has emerged as a promising alternative, effectively reducing pain without opioid receptor activation. Clinical trials indicate its high selectivity, minimal side effects, and no risk of addiction. Addressing the chronic pain epidemic requires a shift toward non-opioid solutions. Expedited clinical trials, expanded research, improved insurance coverage, and education for healthcare providers and patients will be critical in ensuring broader access to safer and more effective pain management strategies.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.